Evidence map›Paper›PMID 39727673›Full record

SynthesisCurrent oncology (Toronto, Ont.)2024

Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic Review.

Jessie Luo, Nizar J Bahlis, Denise Chan, Peter Duggan, Victor H Jimenez-Zepeda, Holly Lee, Sylvia McCulloch, Paola Neri, Jason Tay

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jessie LuoDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Nizar J BahlisDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada.
Denise ChanDepartment of Radiology, University of Calgary, Calgary, AB T2N 4Z5, Canada.
Peter DugganDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada.
Victor H Jimenez-ZepedaDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada.ORCID 0000-0002-9294-9437
Holly LeeDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada.
Sylvia McCullochDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada.
Paola NeriDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada.
Jason TayDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada.

Funding

Calgary Health Foundation n/a
6 · The paper itself

Abstract

In the evaluation of a patient's primary hematologic malignancy, positron emission tomography/computed tomography (PET/CT) imaging may incidentally detect a concerning abnormality suggestive of a second concurrent cancer. Despite accounting for nearly 10% of all cancers diagnosed in Canada, there has yet to be a systematic review focused on the prevalence and significance of these incidental PET/CT findings in the context of primary hematologic malignancies. As such, a systematic search strategy was employed on MEDLINE and Embase to document the prevalence and clinical significance of incidental PET/CT findings suggestive of a second concurrent cancer detected in patients evaluated for their primary hematologic malignancy. Thirteen studies published between 2008 and 2022 were reviewed, including conference abstracts (

Indexed as

Hematologic NeoplasmsIncidental FindingsPositron Emission Tomography Computed TomographyHumansPrevalencehematologic malignanciesincidental findingslymphoproliferative diseasesmyeloma/plasma cell disorderPET/CT

Identifiers

PMID39727673
PMCPMC11674242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.